Viral Clearance Programs

In April 2025, a certain Innovative Drug Research and Development Center Co., Ltd. received the "Drug Clinical Trial Approval Notice" for its self-developed injection for the treatment of advanced solid tumors, approved by the National Medical Products Administration (NMPA). This product is a Class 1 therapeutic biologic new drug independently developed by a certain pharmaceutical company. The successful clinical trial approval marks a significant breakthrough for the company in the field of innovative biologic product development.

Throughout the R&D process of this project, Hengyu Biosafety provided key biosafety testing services, including virus clearance (VC) validation, that meet international submission requirements. With an utmost commitment to service excellence and professional validation expertise, Hengyu worked closely with the client, maintaining efficient communication throughout project management to ensure the validation was completed smoothly and efficiently. Leveraging its internationally compliant quality and technical systems, Hengyu Biosafety has provided robust support for the market launch and global expansion of the innovative drug, helping a Chinese original biologic product reach the world stage.